Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT; EXTEND Clinical Study Group. Guery B, et al. Among authors: karas a. Lancet Infect Dis. 2018 Mar;18(3):296-307. doi: 10.1016/S1473-3099(17)30751-X. Epub 2017 Dec 19. Lancet Infect Dis. 2018. PMID: 29273269 Clinical Trial.
Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study.
Wilcox MH, Cornely OA, Guery B, Longshaw C, Georgopali A, Karas A, Kazeem G, Palacios-Fabrega JA, Vehreschild MJGT. Wilcox MH, et al. Among authors: karas a. Open Forum Infect Dis. 2019 Nov 6;6(11):ofz436. doi: 10.1093/ofid/ofz436. eCollection 2019 Nov. Open Forum Infect Dis. 2019. PMID: 31723569 Free PMC article.
Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial.
Guery B, Georgopali A, Karas A, Kazeem G, Michon I, Wilcox MH, Cornely OA. Guery B, et al. Among authors: karas a. J Antimicrob Chemother. 2020 Apr 1;75(4):1014-1018. doi: 10.1093/jac/dkz549. J Antimicrob Chemother. 2020. PMID: 31960058 Free article. Clinical Trial.
Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE).
Högenauer C, Mahida Y, Stallmach A, Marteau P, Rydzewska G, Ivashkin V, Gargalianos-Kakolyris P, Michon I, Adomakoh N, Georgopali A, Tretter R, Karas A, Reinisch W. Högenauer C, et al. Among authors: karas a. J Antimicrob Chemother. 2018 Dec 1;73(12):3430-3441. doi: 10.1093/jac/dky368. J Antimicrob Chemother. 2018. PMID: 30260412 Clinical Trial.
A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections.
Knitsch W, Vincent JL, Utzolino S, François B, Dinya T, Dimopoulos G, Özgüneş İ, Valía JC, Eggimann P, León C, Montravers P, Phillips S, Tweddle L, Karas A, Brown M, Cornely OA. Knitsch W, et al. Among authors: karas a. Clin Infect Dis. 2015 Dec 1;61(11):1671-8. doi: 10.1093/cid/civ707. Epub 2015 Aug 13. Clin Infect Dis. 2015. PMID: 26270686 Free PMC article. Clinical Trial.
Placing in-vitro heteroresistance in the context of clinical results.
Bassetti M, Echols R, Koren A, Karas A, Longshaw C, Yamano Y, Den Nagata T. Bassetti M, et al. Among authors: karas a. Lancet Infect Dis. 2021 Jul;21(7):908-909. doi: 10.1016/S1473-3099(21)00328-5. Lancet Infect Dis. 2021. PMID: 34174228 No abstract available.
127 results